Unigene to support Stealth phase 1 study for drug candidates

Stealth decided to move forward with Unigene’s platform following the data of an oral feasibility study for its pipeline candidate using the latter’s oral delivery technology relative to competitive technologies.

Unigene chief business officer Gregory Mayes said the ongoing collaboration with Stealth shows the value of Unigene’s Peptelligence platform in the development of novel classes of oral peptide therapeutics.

"This is the second clinical manufacturing services agreement we have executed since launching our Biotechnologies SBU just a little over a year ago," Mayes said.

"We are confident we will convert at least one feasibility study into a definitive licensing agreement within the next 6-9 months."

Stealth CEO Travis Wilson said Unigene has been instrumental in providing its unique technologies to Stealth’s pipeline compounds and opening up additional areas of clinical development.

"Based on the success of our feasibility studies, we look forward to a successful Phase I study for our novel clinical candidate, which could offer a potential breakthrough in the treatment of chronic diseases with unmet needs," Wilson said.

Stealth’s Phase 1 clinical study is expected to begin later this year.